Drug guidance
Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
Condition
Endocrine and metabolic
Kidney
16 September 2025
-
Published on 04 Jun 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Finerenone 10 mg and 20 mg tablets as an add-on therapy for adults with chronic kidney disease and albuminuria associated with type 2 diabetes:
who are receiving concomitant optimal standard treatment which includes an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) at maximum tolerated dose in combination with a sodium-glucose co-transporter 2 (SGLT2) inhibitor, unless contraindicated or not tolerated, and
who have estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) ≥200 mg/g (20 mg/mmol) at the start of treatment.
Funding Status
Finerenone 10 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
Finerenone must be initiated by, or in consultation with, a specialist physician experienced in the management of chronic kidney disease and albuminuria associated with type 2 diabetes.
Treatment with finerenone must be discontinued prior to initiating dialysis.